Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1999-04-09
2000-07-04
McKane, Joseph
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
549479, 549528, 549562, 549563, 560 12, 560 13, 562430, A61K 31341, C07D30740
Patent
active
060839813
DESCRIPTION:
BRIEF SUMMARY
FIELD OF THE INVENTION
This invention relates to compounds that are inhibitors of interleukin-1.beta. converting enzyme. This invention also relates to a method of treatment of stroke, inflammatory diseases, septic shock, reperfusion injury, Alzheimer's disease, shigellosis, and to a pharmaceutically acceptable composition that contains a compound that is an inhibitor of interleukin-1.beta. converting enzyme.
BACKGROUND OF THE INVENTION
The compounds of the present invention are inhibitors of interleukin-1.beta. converting enzyme (ICE) and are useful in treating diseases in which interleukin-1 plays a role.
ICE acts on pro-interleukin-1.beta. (pro-IL-1.beta.) to produce interleukin-1.beta. (IL-1.beta.), which is an inflammatory cytokine. In addition, ICE (Caspase-1) regulates at least four cytokines. ICE activates IL-.beta. and IL-18, and indirectly regulates the production of IL-1.varies. and IFN.gamma.. Several diseases are associated with interleukin-1 activity. Examples of diseases in which interleukin-1 is involved include, but are not limited to, inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease, and neuroinflammatory disorders such as stroke. Other diseases include septic shock, reperfusion injury, Alzheimer's disease, and shigellosis.
Agents that modulate IL-1.beta. activity have been shown to have beneficial in vivo effects. For example, compounds that are interleukin-1 receptor antagonists have been shown to inhibit ischaemic and excitotoxic damage in rat brains. See, for example, Relton J. K., et al., Brain Research Bulletin, 1992;29:243-246. Additionally, ICE inhibitors were shown to reduce inflammation and pyrexia in rats. See Elford P. R., et al., British Journal of Pharmacology, 1995;1 15:601-606.
The compounds of the present invention are also inhibitors of other cysteine proteases in the ICE family. Many of these proteases have only recently been described in the literature. While the nomenclature is still unresolved, the following proteases are representative members of this class of enzymes; Ich-2 (also called Tx or ICErel-II), ICErel-III, Ich-I (also called Nedd-2), CPP-32 (also called apopain and yama), Mch-2, Mch-3 (also called ICE-lap3, CMH-1), and Ced-3. See Henkart P. A., Immunity, 1996;4:195-201. It is recognized that members of this enzyme family play key biological roles in both inflammation and apoptosis (programmed cell death). In particular, Caspase-4 can activate IL-1.beta. and IL-18. It has been shown that a murine homolog of Caspase-4 can activate ICE. Thus, inhibition of Caspase-4 will act to inhibit ICE. See Thornberry N. A., et al., Perspectives in Drug Discovery and Design, 1994;2:389-399.
In addition to its effects on IL-1.beta. production, ICE has been shown to play a role in the production of the inflammatory mediator interferon-.gamma. (Ghayur, et al., Nature, 1997;386(6625):619-623). ICE processes the inactive proform of interferon-.gamma. inducing factor (IGIF; Interleukin-18) to active IGIF, a protein which induces production of interferon-.gamma. by T-cells and natural killer cells. Interferon-.gamma. has been implicated in the pathogenesis of diseases such as inflammatory disorders and septic shock. Therefore, ICE inhibitors would be expected to have beneficial effects in such disease states by effects on interferon-.gamma..
Recently, the nomenclature of these cysteine proteases in the ICE family (also known as Caspases with ICE being known as Caspase-1) has been further defined. The following proteases are representative members of this class of enzymes using the nomenclature described in Alnemri, et al., Cell, 1996;87:171: Caspase-2 (also known as Ich-1); Caspase-3 (also known as CPP32, Yama, and apopain); Caspase4 (also known as TX, Ich-2, and ICE rel-II); Caspase-5 (also known as ICE rel-III); Caspase-6 (also known as Mch2); Caspase-7 (also known as Mch3); Caspase-8 (also known as FLICE and Mch5); Caspase-9 (also known as ICE-LAP6 and Mch6); Caspase-10 (also known as Mch4).
SUMMARY OF THE INVENTION
Provided by the pre
REFERENCES:
patent: 5656627 (1997-08-01), Bemis et al.
Allen Hamish John
Brady Kenneth Dale
Harter William Glen
Lunney Elizabeth Ann
Plummer Mark Stephen
Ashbrook Charles W.
McKane Joseph
Solola Taofiq A.
Warner-Lambert & Company
LandOfFree
Sulfonamide substituted aspartic acid interleukin-1.beta. conver does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sulfonamide substituted aspartic acid interleukin-1.beta. conver, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sulfonamide substituted aspartic acid interleukin-1.beta. conver will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1486981